The GLP is committed to full transparency. Download and review our 2019 Annual Report

A call for action: Genetic testing before prescriptions

| | January 16, 2013
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

Codeine is an opioid pain medication; but if you are a poor metabolizer of a particular enzyme (CYP2D6), you will experience no pain relief from this drug. However, if your doctor could administer something called pharmacogenetic testing, she would know to simply give you morphine (an active metabolite of codeine) instead. For now, this kind of testing isn’t available.

Mary V. Relling, PharmD, the Chair of Pharmaceutical Sciences at St. Jude’s Children Hospital spoke about the need to implement pharmacogenetic testing on Thursday, January 10. A number of  tests have recently emerged that are ready for prime time. When we know that some drugs may have adverse effects for people with  particular genetic phenotypes, it is unethical to prescribe these drugs without knowing the patient’s genetic status.

View the full article here: A Call For Action: Genetic Testing Before Prescriptions

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend